PubMed

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

Diabetes. 2003 Mar;52(3):803-11.PMID: 12606523 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1831-7. Epub 2008 Jun 19.PMID: 18566295 [PubMed - indexed for MEDLINE]Related articlesFree article

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.

Watts GF, Ji J, Chan DC, Ooi EM, Johnson AG, Rye KA, Barrett PH.

Clin Sci (Lond). 2006 Sep;111(3):193-9. Erratum in: Clin Sci (Lond). 2007 Jun;112(12):625. PMID: 16700661 [PubMed - indexed for MEDLINE]Related articles

Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.

Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.

Atherosclerosis. 2002 Aug;163(2):287-96.PMID: 12052475 [PubMed - indexed for MEDLINE]Related articles

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA.

Diabetes. 2002 Aug;51(8):2377-86.PMID: 12145148 [PubMed - indexed for MEDLINE]Related articlesFree article

Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.

Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.

Atherosclerosis. 2001 Mar;155(1):251-60.PMID: 11223449 [PubMed - indexed for MEDLINE]Related articles

Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.

Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.

J Clin Endocrinol Metab. 2002 May;87(5):2283-9.PMID: 11994377 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.

Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T.

J Lipid Res. 2004 Jan;45(1):174-85. Epub 2003 Oct 1.PMID: 14523053 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Feb;57(2):246-54.PMID: 18191056 [PubMed - indexed for MEDLINE]Related articles

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.

Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.

Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1350-6. Epub 2006 Mar 30.PMID: 16574893 [PubMed - indexed for MEDLINE]Related articlesFree article

VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.

Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller U.

J Lipid Res. 1998 Feb;39(2):380-7.PMID: 9507998 [PubMed - indexed for MEDLINE]Related articlesFree article

Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.

Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ.

Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1703-7. Epub 2004 Jul 8.PMID: 15242863 [PubMed - indexed for MEDLINE]Related articlesFree article

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2589-600.PMID: 9409231 [PubMed - indexed for MEDLINE]Related articlesFree article

Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.

Chan DC, Watts GF, Barrett PH, O'Neill FH, Thompson GR.

Obes Res. 2003 Apr;11(4):591-6.PMID: 12690090 [PubMed - indexed for MEDLINE]Related articles

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.

Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.

Am J Cardiol. 2001 Jan 1;87(1):44-8.PMID: 11137832 [PubMed - indexed for MEDLINE]Related articles

Physiologic mechanisms of action of lovastatin in nephrotic syndrome.

Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.

J Lipid Res. 1995 Jan;36(1):188-99.PMID: 7706943 [PubMed - indexed for MEDLINE]Related articlesFree article

The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.

Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

Endocrinology. 1999 Nov;140(11):5293-302.PMID: 10537160 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.

Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.

Atherosclerosis. 2002 Sep;164(1):129-45.PMID: 12119202 [PubMed - indexed for MEDLINE]Related articles

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.

Am J Cardiol. 2003 Apr 15;91(8):956-60.PMID: 12686335 [PubMed - indexed for MEDLINE]Related articles

Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.

Ruel IL, Lamarche B, Mauger JF, Badellino KO, Cohn JS, Marcil M, Couture P.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2600-7. Epub 2005 Oct 13.PMID: 16224048 [PubMed - indexed for MEDLINE]Related articlesFree article